Nicolas Barthelemy Buys 8,550 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWSTGet Rating) Director Nicolas Barthelemy purchased 8,550 shares of Twist Bioscience stock in a transaction on Wednesday, May 11th. The shares were acquired at an average cost of $29.25 per share, for a total transaction of $250,087.50. Following the purchase, the director now owns 13,939 shares in the company, valued at $407,715.75. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

Shares of Twist Bioscience stock opened at $34.29 on Friday. Twist Bioscience Co. has a 1-year low of $25.88 and a 1-year high of $139.99. The firm’s 50-day moving average price is $41.80 and its two-hundred day moving average price is $66.95. The stock has a market capitalization of $1.93 billion, a price-to-earnings ratio of -9.27 and a beta of 1.20.

Twist Bioscience (NASDAQ:TWSTGet Rating) last issued its quarterly earnings data on Thursday, May 5th. The company reported ($1.13) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.13. Twist Bioscience had a negative net margin of 114.96% and a negative return on equity of 28.88%. The business had revenue of $48.13 million for the quarter, compared to analyst estimates of $45.25 million. During the same period last year, the business posted ($0.78) earnings per share. The firm’s quarterly revenue was up 54.2% on a year-over-year basis. As a group, equities analysts expect that Twist Bioscience Co. will post -4.85 EPS for the current fiscal year.

TWST has been the topic of several research reports. Barclays cut their price objective on Twist Bioscience from $60.00 to $40.00 in a research report on Monday, May 9th. The Goldman Sachs Group decreased their target price on Twist Bioscience from $105.00 to $55.00 and set a “neutral” rating for the company in a research note on Wednesday, April 13th. Zacks Investment Research upgraded Twist Bioscience from a “sell” rating to a “hold” rating in a research note on Thursday, March 10th. SVB Leerink reduced their price objective on Twist Bioscience from $110.00 to $70.00 and set a “market perform” rating for the company in a research report on Monday, February 7th. Finally, Robert W. Baird reduced their price objective on Twist Bioscience from $70.00 to $43.00 in a research report on Friday, May 6th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, Twist Bioscience presently has a consensus rating of “Buy” and a consensus price target of $52.00.

Several large investors have recently modified their holdings of TWST. Ameritas Investment Partners Inc. grew its position in Twist Bioscience by 16.0% in the first quarter. Ameritas Investment Partners Inc. now owns 4,293 shares of the company’s stock valued at $212,000 after purchasing an additional 591 shares in the last quarter. Northern Trust Corp grew its position in Twist Bioscience by 9.8% in the first quarter. Northern Trust Corp now owns 512,902 shares of the company’s stock valued at $25,326,000 after purchasing an additional 45,866 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Twist Bioscience by 14.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 416,413 shares of the company’s stock valued at $20,563,000 after purchasing an additional 53,155 shares in the last quarter. Lazard Asset Management LLC grew its position in Twist Bioscience by 73.4% in the first quarter. Lazard Asset Management LLC now owns 1,597 shares of the company’s stock valued at $78,000 after purchasing an additional 676 shares in the last quarter. Finally, American International Group Inc. grew its position in Twist Bioscience by 9.5% in the first quarter. American International Group Inc. now owns 27,482 shares of the company’s stock valued at $1,357,000 after purchasing an additional 2,391 shares in the last quarter.

About Twist Bioscience (Get Rating)

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Featured Stories

Insider Buying and Selling by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.